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Gregory L. Moneta, MD, Section EditorA New Intercostal Artery Management Strategy for Thoracoabdominal
Aortic Aneurysm Repair
Mell MW, Wynn MM, Reeder SB, et al. J Surg Res 2009;54:99-104.
Conclusion: Identification of the anterior spinal artery, artery of Ad-
amkiewicz with magnetic resonance angiography (MRA), and subsequent
selective reimplantation of intercostal arteries during open thoracoabdomi-
nal aneurysm (TAA) repair may serve as an effective additional adjunct in
reducing immediate or delayed paraplegia after repair of TAAs.
Summary: Spinal cord ischemia (SCI) before the use of perioperative
protective measures occurred in 16% to 31% of patients undergoing TAA
repair. Advances in surgical technique, postoperative care, and anesthetic
management have been introduced to address the rate of SCI after TAA
repair. Intraoperative techniques have contributed to a reduction in the
occurrence of SCI with TAA repair. Some have used spinal angiography to
identify critical intercostal arteries; however, the technique has proved
difficult to use and is associated with some risk. Current advances in
computed tomography angiography (CTA) and MRA have made it possible
to noninvasively identify important intersegmental arteries in patients un-
dergoing TAA repair.
In this article the authors introduce a new adjunct for TAA repair that
involves the perioperative identification and selective implantation of critical
intercostal arteries based on preoperative MRA imaging. Included in this
study were patients undergoing TAA repair fromAugust 2005 to September
2007 at the University of Wisconsin. Spinal artery MRA was used to identify
the anterior spinal artery and its major intercostal source preoperatively.
Patients received intraoperative spinal cord protection using standard ad-
juncts. Intercostal arteries felt to be important were preserved or reim-
planted as a button after removal of aortic clamps. Perioperative and demo-
graphic data were retrospectively collected.
MRA of the spinal artery was performed in 27 patients with identifica-
tion of the anterior spinal artery in 85% of the studies. Open repair was
performed in 74% and endovascular repair in 26%. The major intercostal
source artery for the anterior spinal artery was preserved or reimplanted in 13
patients (65%) who underwent open repair. In seven patients (35%), there
was no attempt to preserve or reimplant any intercostal arteries because the
major source artery for the anterior spinal artery was not identified, was
diminutive (1.5 mm in diameter), not accessible, or was associated with
significant calcification. In the patients undergoing reimplantation, a mean
of 1.67 intercostal arteries were reimplanted (range, 1-3). Of the patients
undergoing endovascular repair, the major source intercostal artery for the
anterior spinal artery was covered in all cases. No immediate or delayed
paraplegia developed in any patient in either group.
Comment: The new adjunct here is essentially selective reimplantation of
intercostal arteries based on preoperative MRA imaging. It is impossible to
know whether this strategy will provide any additional benefit in reducing SCI.
In many patients in the open cohort, “important” intercostal arteries were not
reimplanted for technical reasons, and all of the patients who underwent
endovascular repair and in whom “important” intercostal arteries were identi-
fied preoperatively, those arteries were covered during the course of the endo-
vascular repair. No cases of paraplegia were documented in the reimplanted or
non-reimplanted patients treated with open repair, or in any of those treated
with endovascular repair. The potential utility of this approach is that if you are
a selective “reimplanter” of intercostal arteries during TAA repair it is possible,
perhaps, with preoperative MRA of the spinal cord circulation, to identify
precisely which intercostal arteries to reimplant. Whether this strategy will
ultimately result in decreased rates of paraplegia will require a relatively large,
multicenter randomized trial and is very unlikely ever to be performed.
AMS INSIGHT—Absorbable Metal Stent Implantation for Treatment
of Below-the-Knee Critical Limb Ischemia: 6-Month Analysis
Bosiers M, and the AMS INSIGHT Investigators. Cardiovasc Intervent
Radiol 2009;2:424-35.
Conclusion: Implantation of absorbable metal stents (AMSs) in below
knee popliteal arteries is safe but does not result in increased efficacy over
standard percutaneous angioplasty of infrapopliteal vessels.
Summary: Given the poor patency of infrapopliteal percutaneous
revascularizations, a number of strategies are being investigated in patients
with critical limb ischemia who have infrapopliteal occlusive disease. The
permanent presence of an artificial implant may contribute to restenosis of a
stented vessel. Stenting technology has led to the development of temporary
implants composed of biocompatible materials that can support the vessel
during the period of high risk for recoil but then completely degrade over
the long term. Bioabsorbable stents serve as a means to mechanically preventvessel recoil while avoiding the theoretic disadvantage of a long-term metal-
lic implant.
This study investigated the safety and efficacy of AMSs in infrapopliteal
arteries. Clinical follow-up was at 1 and 6 months, and efficacy was deter-
mined at 6 months by angiogram. There were 117 patients with 149 lesions
and critical limb ischemia (Rutherford categories 4 and 5) who were ran-
domized to implantation of an AMS (60 patients, 74 lesions) or stand-alone
percutaneous transluminal angioplasty (PTA; 57 patients, 75 lesions). Seven
PTA group patients crossed over to the stenting group. Lesions stented had
to have a50% diameter reduction with a vessel diameter of between 3 and
3.5 mm and a lesion length of 15 mm. The primary safety end point was
absence of major amputation or death30 days after the index intervention.
Primary efficacy end point was 6-month angiographic patency.
The 30-day complication rate for patients randomized to PTA alone
was 5.3% (3 of 57) and that for AMS implantation was 5% (3 of 60). An
intention to treat analysis showed angiographic patency for lesions treated
with AMS (31.8%) was lower than that for patients treated with PTA alone
(58.0%; P  .013).
Comment: The study confirms low short-term patency of infrapopli-
teal percutaneous interventions. It is disappointing that the bioabsorbable
stents did not improve patency of infrapopliteal interventions, and in fact,
appeared to be associated with worse results. The current results do not
support the positive clinical outcome of the initial AMS findings in a small
cohort of patients (J Endovasc Ther 2005;12:1-5). The technology appears
safe, but the stent will need to be improved and re-evaluated before
commercial use can be considered an option. Once again, the complex
biology of atherosclerosis and intimal hyperplasia appears to have beaten
some clever engineers.
Aortic Arch Plaques and Risk of Recurrent Stroke and Death
Di Tullio MR, Russo C, Jin Z, and the Patent Foramen Ovale in Crypto-
genic Stroke Study Investigators. Circulation 2009;19:2376-82.
Conclusion: Large aortic plaques are associated with an increased risk
of recurrent stroke and death at 2 years, even when patients are treated with
aspirin or warfarin therapy.
Summary: Large aortic plaques (4 mm), as determined by transesoph-
ageal echocardiography (TEE), confer an increase risk of stroke (J Am Coll
Cardiol 1994;23:1085-90). Ulceration and superimposed thrombi appear
to increase risk as well (Am Heart J 2000;139:329-36). It is assumed,
without much evidence, that anticoagulation or antiplatelet agents, or both,
prevent stroke in patients with large aortic plaques. In this study the authors
sought to define event rates in patients with stroke who had large aortic
plaques. Patients were randomly assigned in a double-blind fashion to
warfarin or aspirin treatment. The primary end point was recurrent ischemic
stroke or death resulting from any cause. Recurrent ischemic stroke was a
new lesion on magnetic resonance imaging or computed tomography scan-
ning. If new lesions were absent, a clinical syndrome consistent with stroke
lasting 24 hours was considered an end point.
There were 516 patients with ischemic stroke who were double-blindly
randomized. Large plaques (4 mm) were present in 19.6% of patients, and
large complex plaques, defined as those with mobile components or ulcer-
ations, were seen in 8.5%. During the 2-year follow-up period, large plaques
were associated with an increase risk of events (adjusted hazard ratio [HR],
2.12; 95% confidence interval [CI], 1.04-4.32). The HR was also increased
in those with complex plaque morphology (HR, 2.55; 95% CI, 1.10-5.89).
In patients with cryptogenic stroke, the HR was higher for both large
plaques (HR, 6.42; 95% CI, 1.62-25.46) and large complex plaques (HR,
9.50; 95% CI, 1.92-47.10). There were no differences in event rates in the
warfarin and aspirin groups compared with the overall study population
(16.4% vs 15.8%; P  0.43).
Comment: In this study large aortic plaques were associated with a
doubling of the risk of recurrent stroke and death despite medical therapy.
There was no difference between aspirin and warfarin therapy, and both
therapies were relatively ineffective. The HRs observed in this report ap-
peared only slightly lower than those previously reported from studies where
treatment was not randomized or even not prescribed (J Am Coll Cardiol
1994;23:1085-90). The study suggests that neither warfarin nor aspirin
significantly affect the risk of stroke associated with large aortic plaques.
Aspirin vs Anticoagulation in Carotid Artery Dissection: A Study of
298 Patients
Georgiadis D, Arnold M, von Buedingen HC, et al. Neurology 2009;72:
1810-5.
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